Golden, Colorado—June 2, 2015 Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of cardiac and neural cells that are differentiated from human MSCs.  Our new products include cardiomyocytes, alpha motor neurons and neural stem cells.  In support of this commercial launch, we have also launched an improved and updated website featuring enhanced functionality and improved access to product information.  Our newly developed cardiomyocytes and alpha motor neurons compliment existing stem cell-derived cells for use in cell-based assays of drug toxicity:  MSC-derived osteoblasts and chondrocytes.  Vitro Biopharma has additional cell types in development including dopaminergic neurons, proximal tubule epithelial cells and podocytes.  The latter cells will enable cell-based assays for renal toxicity.

These new products provide additional options for in-vitro testing of drug & drug candidate toxicity using human cells.   Well-characterized human cells provide a platform for relevant toxicology screening as compared to animal cells.  Furthermore, co-culture systems including human hepatocytes extend screening to include drug metabolites as well as the drug or drug candidate itself.  Drug metabolite toxicity may not be adequately detected using animal cells & tissues.  These advances translate to increased detection of toxicity issues at the pre-clinical stage of drug development and thus, enhanced efficiency of new drug development.  Drug toxicity is a major cause of drug recalls and is also a source of significant medical problems.  Furthermore, certain toxicities result from drug interactions that may be detectable in in-vitro human cell systems representing primary organ groups such as cardiac, neural and renal cells.   An additional benefit of human cell-based assays is a diminished need for animal testing in the development of new drugs.

Dr. Jim Musick, Vitro Biopharma’s President & CEO, said, “We are pleased to announce our latest new products and improved website.  This represents new revenue opportunities for the Company and expands our cell-based assay offerings as well.  Drug toxicology is a critical issue for the development of new drugs and evaluation of current drugs.  Being able to utilize a human cell-based model as a tool for analytical toxicology holds many benefits including potential co-culture with multiple cell types to determine effects of hepatocyte-derived drug metabolites and toxic effects of drug interactions. We are exploring potential collaboration in this field and also maintain capability as a GMP-compliant cell supplier for high-throughput applications.  Another aspect of this work is recognition of expanded differentiation capacity of MSCs.  While previously thought to be limited to tri-lineage differentiation to adipocytes, osteoblasts and chondrocytes, we now can generate neural stem cells and certain neural lineages from mesodermal cells.  This challenges previous developmental concepts and suggests significant expansion of the potential therapeutic benefit of MSCs.” 

About Vitro Biopharma

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes.  Vitro Biopharma also owns a pending patent for methods and materials related to treatment of neurological conditions by activation of neural stem cells.  Vitro Biopharma’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado.  Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation.  Our cell lines also include cancer-associated fibroblasts (CAFs) and MSC-derived progenitor cells, including neural stem cells as well as a growing line of terminally differentiated cells: alpha-motor neurons, osteoblasts, chondrocytes, cardiomyocytes, etc.  Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com).  Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems.  Through Neuromics, Vitro Biopharma has also partnered with Dr. Josef Smarda in central Europe to provide products and services related to treatment of patients with autism, autoimmunity and other conditions.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

Source: Vitro Diagnostics, Inc.